ScholarLens Back to search
2011•Journal of Clinical Medicine in PracticeRequires access

Clinical observation of Nedaplatin combined with docetaxel in treatment of advanced esophageal cancer

Gui‐Nan Lin

Open publisher page 0 citations

Abstract

Objective To observe the efficacy and safety of Nedaplatin combined with docetaxel in the treatment of advanced esophageal cancers.Methods 43 patients were enrolled.Amongst 22 patients undergoing Cis/Doc,21 patients undergoing Ned/Doc.Cis/Doc regimen included cisplatin 25 mg/m2 days1 to 3 and docetaxel 75 mg/m2 day1,while Ned/Doc comprised of nedaplatin 25 mg/m2 days1 to 3 and docetaxel 75 mg/m2 day1.Both regimens were administered intravenously every 21 days and no more than six cycles.Results There was not significantly difference between the both groups in ORR,CBR,TTP and MST.Most of the side effects was manageable.Gastrointestinal toxicity was mainly found in Cis/Doc group,while hematologic toxicity in Ned/Doc group.Conclusion Although they had similar efficacy,Ned/Doc may have an advantage over Cis/Doc with respect to side effcets.

About this research paper

What this paper is about

Objective To observe the efficacy and safety of Nedaplatin combined with docetaxel in the treatment of advanced esophageal cancers.Methods 43 patients were enrolled.Amongst 22 patients undergoing Cis/Doc,21 patients undergoing Ned/Doc.Cis/Doc regimen included cisplatin 25 mg/m2 days1 to 3 and docetaxel 75 mg/m2 day1,while Ned/Doc comprised of nedaplatin 25 mg/m2 days1 to 3 and docetaxel 75 mg/m2 day1.Both regimens were administered intravenously every 21 days and no more than six cycles.Results There was not significantly difference between the both groups in ORR,CBR,TTP and MST.Most of the side effects was manageable.Gastrointestinal toxicity was mainly found in Cis/Doc group,while hematologic toxicity in Ned/Doc group.Conclusion Although they had similar efficacy,Ned/Doc may have an advantage over Cis/Doc with respect to side effcets.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To observe the efficacy and safety of Nedaplatin combined with docetaxel in the treatment of advanced esophageal cancers.Methods 43 patients were enrolled.Amongst 22 patients undergoing Cis/Doc,21 patients undergoing Ned/Doc.Cis/Doc regimen included cisplatin 25 mg/m2 days1 to 3 and docetaxel 75 mg/m2 day1,while Ned/Doc comprised of nedaplatin 25 mg/m2 days1 to 3 and docetaxel 75 mg/m2 day1.Both regimens were administered intravenously every 21 days and no more than six cycles.Results There was not significantly difference between the both groups in ORR,CBR,TTP and MST.Most of the side effects was manageable.Gastrointestinal toxicity was mainly found in Cis/Doc group,while hematologic toxicity in Ned/Doc group.Conclusion Although they had similar efficacy,Ned/Doc may have an advantage over Cis/Doc with respect to side effcets.

Key concepts: Docetaxel, Nedaplatin, Medicine, Regimen, Toxicity, Internal medicine, Cisplatin, Chemotherapy

Back to paper searchBrowse research topicsOriginal source
Clinical observation of Nedaplatin combined with docetaxel in treatment of advanced esophageal cancer — Research Paper | ScholarLens